下载App
扫码立即下载
  • 下载App

    扫码立即下载

  • 在线客服

    登录后咨询在线客服
+
恭喜您!
成功领取价值超 5000港元/年的高级行情
前往体验 >>
多维分析
公司估值 资金追踪 卖空分析
06160 百济神州
122.000
+0.100+0.08%
显示同比
不显示
隐藏空行
(Q6)2022/06/30(Q3)2022/03/31(FY)2021/12/31(Q9)2021/09/30
Per Share IndicaTor
Operating Cash Flow Per Share
-- -- -- -- 9.38% -7.6063 -- --
Cash Flow Per Share
-- -- -- -- 248.44% 17.5286 -- --
Operating Income Per Share
-22.55% 3.7846 -54.48% 1.7988 241.06% 6.8892 349.64% 6.1747
Net Asset Per Share
-- -- -- -- 44.5% 36.5636 -- --
Basic Earning Per Share
-- -- -- -- 19.94% -9.1237 -- --
Diluted  Earning Per Share
-- -- -- -- 19.94% -9.1237 -- --
Profitability
Gross Profit Ratio
-13.12% 78.956% -16.79% 78.724% 11.48% 85.981% 15.29% 87.908%
Operating Profit Ratio
-154.35% -136.175% -1348.31% -144.569% 77.21% -122.312% 83.96% -90.096%
Net Profit Ratio
-183.38% -155.157% -1390.47% -141.630% 76.81% -120.154% 84.08% -86.012%
Earning Before Tax Ratio
-172.61% -151.008% -1445.44% -137.382% 76.66% -122.299% 83.74% -88.515%
ROE
-- -- -- -- 57.58% -28.016% -- --
ROA
-69.17% -12.596% -547.79% -5.221% 55.04% -19.887% 51.29% -15.238%
Yield Quality
Operating Cash To Total Revenue
-- -- -- -- 73.43% -110.409% -- --
Capital Structure
Debt Assets Ratio
-18.95% 28.132% -14.72% 26.627% -10.1% 27.793% 59.97% 36.495%
Equity Multipler
-- -- -- -- -4.32% 1.3849 -- --
Debt Equity Ratio
-26.36% 39.145% -20.06% 36.291% -13.99% 38.491% 94.44% 57.469%
Current Assets To tatal Assets
-- -- -- -- -0.57% 88.063% -- --
Non Current Assets To Total Assets
-- -- -- -- 4.45% 11.937% -- --
Current Liabilities To tatal Liabilities
-- -- -- -- 7.2% 66.566% -- --
Non Current Liabilities To Total Liabilities
-- -- -- -- -11.79% 33.434% -- --
Solvency
Current Ratio
-- -- -- -- 3.17% 4.76 -- --
Quick Ratio
-- -- -- -- 1.71% 4.6083 -- --
Operating Profit To Current Liabilities
-- -- -- -- 41.66% -0.8995 -- --
Operrating Cash Flow To Current Liabilities
-- -- -- -- 31.98% -0.8119 -- --
Share Equity Without Minority Interest To Total Liabilities
-- -- -- -- 16.26% 2.598 -- --
Operating Cash Flow To Total Liabilities
-- -- -- -- 27.09% -0.5405 -- --
Operating Profit To Total Liabilities
-101.49% -0.4253 -637.56% -0.2075 37.46% -0.5987 51.34% -0.4494
Operating Capacity
Inventory Turnover(T)
-- -- -- -- -16.91% 0.9952 -- --
Current Assets Turnover(T)
-- -- -- -- 86.35% 0.1875 -- --
Fixed Assets Turnover(T)
-- -- -- -- 142.74% 2.4942 -- --
Total Assets Turnover(T)
-40.3% 0.0812 -65.3% 0.0369 93.45% 0.1655 204.92% 0.1772
Growth Ability
Operating Revenue GR 3Y
-86.77% 102.662% -83.21% 292.835% 2320.57% 490.783% -- --
Gross Income GR 3Y
-90.34% 78.398% -85.24% 284.682% 9263.54% 493.975% -- --
Operating Profit GR 3Y
-422.83% -241.455% -194.88% -154.397% 94.59% -102.947% -- --
EBT GR 3Y
-442.59% -291.020% -196.31% -150.703% 95.45% -107.615% -- --
Net Profit GR 3Y
-433.58% -297.573% -196.92% -157.656% 93.01% -108.753% -- --
Net Profit Attributable To The Parent Company GR 3Y
-428.27% -298.850% -197.14% -158.316% 92.97% -108.835% -- --
Total Assets GR 3Y
6.24% 244.845% 12.97% 268.229% -35.34% 282.550% -- --
Share Equity Without Minority Interest GR 3Y
-- -- -- -- -45.84% 257.305% -- --
Equity GR 3Y
25.27% 239.165% 36.36% 261.680% -45.01% 254.362% -- --
Total Liabilities GR 3Y
-24.36% 260.258% -30.56% 287.564% -1.33% 382.202% -- --
Basic Earning Per Share GR 3Y
-- -- -- -- 96.44% -25.247% -- --
Net Assets Per Share GR 3Y
-- -100.000% -- -100.000% -- 107.874% -- --
Other Indicators
Currency Unit
港元港元港元港元

Q6、Q9、FY为累计季报:Q6 为中期报告;Q9 为第三季报;FY为年报。

环比数据来源于季报,环比 = (本期 - 上期)/上期 * 100%

公司概况 更多
百济神州有限公司是一家全球性生物技术公司。该公司专注于发现、开发、制造和商业化药物,以改善治疗效果并扩大全球患者的准入。该公司已发现并开发了三种经批准的药物,包括BRUKINSA,一种用于治疗各种血癌的Bruton酪氨酸激酶(BTK)小分子抑制剂,用于治疗各种实体瘤和血癌的抗PD-1抗体免疫疗法tislelizumab,以及聚ADP核糖聚合酶1(PARP1)和PARP2的选择性小分子抑制剂pamiparib。该公司还有其他处于临床阶段的产品,包括BGB-283、BGB-3245、BGB-11417、BGB-A445、BGB-A425、BGB-15025、BGB-A333、BGB-A1217和BGB-10188。该公司在五大洲的约30个国家设有办事处,包括美国、中国、欧洲和澳大利亚。
董事长: 欧雷强
所属市场: 香港主板
上市日期: 2018/08/08
富途热股榜
港股美股沪深
交易热度搜索热度资讯热度
名称代码最新价涨跌幅

加载中...

自选
回到顶部